The Leipzig Prospective Drug-Eluting Balloon-Registry　– Outcome of 484 Consecutive Patients Treated for Coronary In-Stent Restenosis and De Novo Lesions Using Paclitaxel-Coated Balloons –

Abstract

Circulation Journal Official Journal of the Japanese Circulation Society http://www. j-circ.or.jp in DES is associated with worse outcomes than with ISR in BMS. 13 Currently, there is no clear consensus about the optimal management of ISR. Intracoronary stenting is still the preferred treatment in patients with ISR after DES or BMS implantation. 9,14-16 However, drug-eluting balloons (DEB) provide potential advantages: 17 rapid release of high drug concentrations and homogeneous drug delivery to the vessel wall, absence of stent and polymer, reduced chronic inflammation and shorter duration of antiplatelet therapy. The recently published SeQuent Please World Wide Registry 18 confirmed a low TLR rate of 5.2% at 9.4 months' follow-up in patients treated with a DEB for BMS restenosis.The ISAR-DESIRE 3 trial showed non-inferiority of the he introduction of drug-eluting stents (DES) significantly reduced the rates of restenosis and target lesion revascularization (TLR), because of inhibition of cellular proliferation as compared with bare-metal stents (BMS). 1 Despite advances in treatment, in-stent restenosis (ISR) still remains the primary concern after percutaneous coronary intervention (PCI) using DES 2-7 and is surprisingly high ranging from 3% to 20%, especially in an all-comers scenario.

Intracoronary Imaging Versus Coronary Angiography to Guide Drug-Coated Balloon Intervention in Coronary Artery Disease: A Propensity-Matched Pilot Study Analysis

“…16 The incidence of cardiac death was 1.8% in our cohort, which is consistent with DCB safety outcome concluded from other DCB studies. 17,18 Previous DCB trials have reported low MI rates at long period follow-up. 18,19 This is comparable to the 2.4% incidence of MI in the current study.…”

Drug-Eluting Balloons in the Treatment of Coronary De Novo Lesions: A Comprehensive Review

“…Twenty-five percent received bailout BMS implantation which was not associated with a less favorable outcome (MACE 7.1% with additional BMS and 9.5% without BMS) [41]. The prospective Leipzig Registry evaluated the clinical outcome in 484 patients treated with a SeQuent Please DEB [42]. De novo vessel disease was seen in 76 patients (15.7%).…”

“…In de novo lesions, no TLR was seen after 27 months. MACE was defined differently than in other studies and was thus difficult to compare [42]. Being the second largest real world registry, the SeQuent Please Small Vessel “PCB Only” Registry was a prospective multicenter study assessing the safety and efficacy of the SeQuent Please DEB in 447 patients [35].…”

3D‐Printed Multidrug‐Eluting Stent from Graphene‐Nanoplatelet‐Doped Biodegradable Polymer Composite

“…Patients with blocked coronary arteries undergoing PCI are given the choice to receive either drug‐eluting stents (DESs) or bare metal stents (BMSs) to restore the normal blood flow. Currently, bare metal stents have ≈30% chance of restenosis occurring within a six‐month period . Long‐term metallic stents may also interfere with computer tomography (CT) and magnetic resonance imaging.…”

“…A complete degradation period for polymer based stents including poly‐ l ‐lactic acid (PLLA) and poly‐ l ‐caprolactone (PCL) have been reported as ca. two years while for polyglycolic acid were found to be 6–12 months . An ideal period for stent degradation would finally depend on the targeted disease with requirement of small or longer time interventions.…”